Roles of p15Ink4b and p16Ink4a in myeloid differentiation and RUNX1-ETO-associated acute myeloid leukemia

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1101-1111

  Ko, Rose M ^a   Kim, Hyung Gyoon ^b   Wolff, Linda ^c   Klug, Christopher A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of California   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Hematopoiesis; p15Ink4b; p16Ink4a; RUNX1 ETO

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; HYBRID PROTEIN; PROTEIN ETO; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; PRIMER DNA; RUNX1 PROTEIN, MOUSE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPLANTATION; ANIMAL; C57BL MOUSE; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL;

EID: 41949094721     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.10.012     Document Type: Article

References (40)

1. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
2. Rowley J.D. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann de Genetique 16 2 (1973) 109-112
3. Nucifora G., and Rowley J.D. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86 1 (1995) 1-14
4. Downing J.R. The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol 106 2 (1999) 296-308
5. Erickson P., Gao J., Chang K.S., Look T., Whisenant E., Raimondi S., et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80 7 (1992) 1825-1831
6. Downing J.R., Head D.R., Curcio-Brint A.M., Hulshof M.G., Motroni T.A., Raimondi S.C., et al. An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation. Blood 81 11 (1993) 2860-2865
7. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 12 7 (1993) 2715-2721
8. Lutterbach B., Westendorf J.J., Linggi B., Patten A., Moniwa M., Davie J.R., et al. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18 12 (1998) 7176-7184
9. Gelmetti V., Zhang J., Fanelli M., Minucci S., Pelicci P.G., and Lazar M.A. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18 12 (1998) 7185-7191
10. Higuchi M., O'Brien D., Kumaravelu P., Lenny N., Yeoh E.J., and Downing J.R. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1 1 (2002) 63-74
11. Rhoades K.L., Hetherington C.J., Harakawa N., Yergeau D.A., Zhou L., Liu L.Q., et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 96 6 (2000) 2108-2115
12. Yuan Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C.J., et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98 18 (2001) 10398-10403
13. de Guzman C.G., Warren A.J., Zhang Z., Gartland L., Erickson P., Drabkin H., et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22 15 (2002) 5506-5517
14. Schwieger M., Lohler J., Friel J., Scheller M., Horak I., and Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 196 9 (2002) 1227-1240
15. Westendorf J.J., Yamamoto C.M., Lenny N., Downing J.R., Selsted M.E., and Hiebert S.W. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 18 1 (1998) 322-333
16. Pabst T., Mueller B.U., Harakawa N., Schoch C., Haferlach T., Behre G., et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7 4 (2001) 444-451
17. Burel S.A., Harakawa N., Zhou L., Pabst T., Tenen D.G., and Zhang D.E. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 21 16 (2001) 5577-5590
18. Kummalue T., Lou J., and Friedman A.D. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol 22 23 (2002) 8278-8291
19. Li X., Xu Y.B., Wang Q., Lu Y., Zheng Y., Wang Y.C., et al. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. J Cell Physiol 208 3 (2006) 594-601
20. Lou J., Cao W., Bernardin F., Ayyanathan K., Rauscher I.F., and Friedman A.D. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF-a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene 19 22 (2000) 2695-2703
21. Strom D.K., Nip J., Westendorf J.J., Linggi B., Lutterbach B., Downing J.R., et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 275 5 (2000) 3438-3445
22. Bernardin-Fried F., Kummalue T., Leijen S., Collector M.I., Ravid K., and Friedman A.D. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem 279 15 (2004) 15678-15687
23. Peterson L.F., Yan M., and Zhang D.E. The p21waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood 109 10 (2007) 4392-4398
24. Liu Y., Cheney M.D., Gaudet J.J., Chruszcz M., Lukasik S.M., Sugiyama D., et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 9 4 (2006) 249-260
25. Linggi B., Muller-Tidow C., van de Locht L., Hu M., Nip J., Serve H., et al. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Nat Med 8 7 (2002) 743-750
26. Yang G., Khalaf W., van de Locht L., Jansen J.H., Gao M., Thompson M.A., et al. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 25 14 (2005) 5869-5879
27. Herman J.G., Jen J., Merlo A., and Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56 4 (1996) 722-727
28. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12 6 (1998) 845-859
29. Wong I.H., Ng M.H., Huang D.P., and Lee J.C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95 6 (2000) 1942-1949
30. Chim C.S., Wong A.S., and Kwong Y.L. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias. Ann Hematol 82 12 (2003) 738-742
31. Wolff L., Garin M.T., Koller R., Bies J., Liao W., Malumbres M., et al. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene 22 58 (2003) 9265-9274
32. Ogawa S., Hangaishi A., Miyawaki S., Hirosawa S., Miura Y., Takeyama K., et al. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86 4 (1995) 1548-1556
33. INK4A characterize the major types of hematological malignancies. Cancer Res 57 5 (1997) 837-841
34. Cotta C.V., Zhang Z., Kim H.G., and Klug C.A. Pax5 determines B- versus T-cell fate and does not block early myeloid-lineage development. Blood 101 11 (2003) 4342-4346
35. Passegue E., Wagers A.J., Giuriato S., Anderson W.C., and Weissman I.L. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med 202 11 (2005) 1599-1611
36. Anderson M.T., Tjioe I.M., Lorincz M.C., Parks D.R., Herzenberg L.A., Nolan G.P., et al. Simultaneous fluorescence-activated cell sorter analysis of two distinct transcriptional elements within a single cell using engineered green fluorescent proteins. Proc Natl Acad Sci USA 93 16 (1996) 8508-8511
37. Latres E., Malumbres M., Sotillo R., Martin J., Ortega S., Martin-Caballero J., et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 19 13 (2000) 3496-3506
38. Rosu-Myles M., Taylor B.J., and Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol 35 3 (2007) 394-406
39. Nucifora G., Larson R.A., and Rowley J.D. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 82 3 (1993) 712-715
40. Miyamoto T., Weissman I.L., and Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 97 13 (2000) 7521-7526